Lead Plaintiff Deadline: September 06, 2022
Please Upload related files below
Fill in below.
Looking for more?
common stock between September 15, 2020, and June 13, 2022
(1) the Company’s flagship product, Tablo Hemodialysis System (“Tablo”), would require an additional 510(k) application to be filed with The United States Food and Drug Administration (“FDA”), as defendants had “continuously made improvements and updates to Tablo over time since its original clearance”; (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols; (3) the Company’s inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a “shipment hold” and marketing suspension, leaving the Company unable to sell Tablo for home use; and (4) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times.
In order to be included in the lawsuit, you must have incurred a loss on shares of Outset Medical, either: A) purchased or acquired during the class period listed above, if applicable; or B) pursuant to the Initial Public Offering (IPO) of Outset Medical, if applicable.
If you suffered a loss in Outset Medical during the relevant time frame, or pursuant to Outset Medical’s IPO if listed above, you have until September 06, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.